In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 15, No. 704 ( 2023-07-12)
Abstract:
Plasmodium vivax is the second most common cause of malaria in humans and currently lacks an effective vaccine. Here, Hou et al . report encouraging clinical trial results testing the safety and efficacy of two vaccine candidates, both based on the P. vivax Duffy-binding protein region II (PvDBPII). One of the vaccine candidates, an adjuvanted PvDBPII protein vaccine, elicited the strongest antibody responses, particularly when delivered in a delayed dosing regimen. This correlated with the superior control of parasitemia when vaccinees underwent a controlled human malaria infection. These data, plus a favorable safety profile, support further clinical testing of this vaccine regimen. —Courtney Malo
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.adf1782
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2023
Permalink